Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Gross Margin (2016 - 2019)

Plus Therapeutics (PSTV) has disclosed Gross Margin for 9 consecutive years, with 83.78% as the latest value for Q1 2019.

  • Quarterly Gross Margin rose 6299.0% to 83.78% in Q1 2019 from the year-ago period, while the trailing twelve-month figure was 61.05% through Mar 2019, up 4610.0% year-over-year, with the annual reading at 82.48% for FY2018, 7705.0% up from the prior year.
  • Gross Margin for Q1 2019 was 83.78% at Plus Therapeutics, down from 96.69% in the prior quarter.
  • The five-year high for Gross Margin was 96.69% in Q4 2018, with the low at 21.15% in Q1 2017.
  • Average Gross Margin over 5 years is 31.31%, with a median of 27.04% recorded in 2017.
  • The sharpest move saw Gross Margin plummeted -7861bps in 2017, then soared 9231bps in 2018.
  • Over 5 years, Gross Margin stood at 49.16% in 2015, then dropped by -28bps to 35.54% in 2016, then crashed by -88bps to 4.38% in 2017, then soared by 2107bps to 96.69% in 2018, then dropped by -13bps to 83.78% in 2019.
  • According to Business Quant data, Gross Margin over the past three periods came in at 83.78%, 96.69%, and 26.81% for Q1 2019, Q4 2018, and Q3 2018 respectively.